FDA Patent Listing Review System Suggested By Paxil Appeals Court
This article was originally published in The Tan Sheet
Executive Summary
An FDA system to review patents for Orange Book listing would be feasible, U.S. Federal Circuit Judge Jay Plager suggested Feb. 4
You may also be interested in...
FDA “Ministerial” Approach To Patent Listings Upheld By Appeals Court
An appeals court's dismissal of Apotex' lawsuit against FDA relating to patent listings affirms a key provision in the final rule reforming Hatch/Waxman
FDA “Ministerial” Approach To Patent Listings Upheld By Appeals Court
An appeals court's dismissal of Apotex' lawsuit against FDA relating to patent listings affirms a key provision in the final rule reforming Hatch/Waxman
FDA “Ministerial” Approach To Patent Listings Upheld By Appeals Court
An appeals court's dismissal of Apotex' lawsuit against FDA relating to patent listings affirms a key provision in the final rule reforming Hatch/Waxman